Filing Flows › Comparisons › AGIO vs TNGX
Agios Pharmaceuticals vs Tango Therapeutics: AGIO and TNGX compared
Agios Pharmaceuticals is the larger company: $55.4M of revenue in its latest quarter (Q3 2026) against $53.8M for Tango Therapeutics (Q3 2025). Tango Therapeutics is growing faster (+364% against +330% a year earlier). Tango Therapeutics is more profitable, with an operating margin of 26.2% against -139.3%.
Where the money goes: AGIO and TNGX
Agios Pharmaceuticals (AGIO) · Q3 2026
Agios Pharmaceuticals, Q3 2026: revenue $55.4M (+330% year over year), operating margin -139.3%, net loss $65.0M, operating cash flow −$59.2M. The chart follows the revenue to costs, profit and cash.
Tango Therapeutics (TNGX) · Q3 2025
Tango Therapeutics, Q3 2025: revenue $53.8M (+364% year over year), operating margin 26.2%, net earnings $15.9M, operating cash flow −$31.0M. The chart follows the revenue to costs, profit and cash.
| Agios Pharmaceuticals (AGIO) | Tango Therapeutics (TNGX) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2025 |
| Revenue | $55.4M | $53.8M |
| Revenue growth, Y/Y | +330% | +364% |
| Operating margin | -139.3% | 26.2% |
| Net earnings | −$65.0M | $15.9M |
| Net margin | -117.4% | 29.5% |
| Operating cash flow | −$59.2M | −$31.0M |
| Market value | $1.9B | — |
| Analysts’ mean target | $45.88 | — |
Questions
Which is bigger, Agios Pharmaceuticals or Tango Therapeutics?
Agios Pharmaceuticals is the larger company: $55.4M of revenue in its latest quarter (Q3 2026) against $53.8M for Tango Therapeutics (Q3 2025).
Is Agios Pharmaceuticals or Tango Therapeutics growing faster?
Tango Therapeutics is growing faster (+364% against +330% a year earlier).
Which is more profitable, Agios Pharmaceuticals or Tango Therapeutics?
Tango Therapeutics is more profitable, with an operating margin of 26.2% against -139.3%.
More: Agios Pharmaceuticals earnings · how Agios Pharmaceuticals makes money · Tango Therapeutics earnings · how Tango Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Nov 4, 2025). Fiscal quarters can end on different dates. Not investment advice.